Status:
COMPLETED
Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
Celgene Corporation
Conditions:
Gram-negative Bacterial Infections
Eligibility:
All Genders
18+ years
Brief Summary
The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) \[measured as defined daily doses per 1000 patient da...
Detailed Description
The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with Gram negative infections treated with piperacillin/tazobactam and/or piperacillin
Exclusion
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00177814
Start Date
September 1 2005
End Date
June 1 2017
Last Update
June 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213